| Why carry out this study? |
| Guidelines for treatment of multidrug-resistant (MDR) bacteria rely on newly approved antibiotics. |
| We aimed to assess how much would it cost to base treatment for multidrug-resistant bacterial infections on those new antibiotics. |
| What was learned from the study? |
| Annual incremental cost of new antibiotics could reach 30–500 million USD for some bacteria. |
| Lack of solid evidence for superior effectiveness of new antibiotics for these bacteria complicates treatment decisions. |
| Cost should be part of the discussion while considering use of newly approved antibiotics until further evidence for effectiveness accumulates. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.